No profile data available.
Organon & Co. (OGN) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Jersey City, United States, with about 10,000 full-time employees.
It reported revenue of $6.22 billion for fiscal year 2025, down 2.9% from fiscal year 2024, and net income of $187.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.56 billion, down 2.3% from a year before. Europe and Canada was its largest region in fiscal year 2025, with 26% of revenue. Its market capitalization was $3.63 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Organon & reported $6.22 billion in revenue for fiscal year 2025, down 2.9% from $6.40 billion in fiscal year 2024. In Q2 2026 revenue was $1.56 billion.
Europe and Canada: 26% of revenue by region in fiscal year 2025, followed by United States (26%).
$3.63 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (GEDSF), Aspen Pharmacare Holdings Limited (APNHY), CMS (CHSYF), Viking Therapeutics, Inc. (VKTX).